REASONS TO ATTEND IN 2015:• Address the provocative issue of tumour genetic heterogeneity in

immunotherapy• Understand the angiogenic process in both normal and tumour

and development• Gain key industry perspective in combination therapies to advance

immune-oncology vaccines and enhance patient outcomes • Envision RNA - vaccinology for building the next-generation of RNA

immunogens• Look forward to our lead sponsored session:

Northwest Biotherapeutics's personalised DCVax® platformtechnology that actively mobilizes the immune system against solidtumour targets!

SMi Presents the 4th Annual Conference on...

16 - 17

SEPT2015Marriott Regents Park Hotel, London, UK

Cancer Vaccines

PLUS TWO INTERACTIVE PRE-CONFERENCE WORKSHOPSTuesday 15th September 2015, Marriott Regents Park Hotel, London, UK

www.cancervaccinesevent.com Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

...Advancing Immuno-Oncology

@SMIPHARM

Workshop A

Stress is Good: Heat Shock Protein 70 as a Next-GenerationTheranostic with Broad Applicability in Oncology

Workshop Leaders: Alan Graham Pockley, 1Associate Director & Professor of Immunobiology, 2CEO,3Founder and CEO 1Nottingham Trent University, 2Multimmune GmbH, 3Chromocyte Ltd, UK andDr. Gabriele Multhoff, 1University Professor in Experimentelle Radioonkologie und Strahlenbiologie,

2Group Leader, 1Technische Universität München, 1Helmholz Zentrum München 8.30am - 12.30pm

BOOK BY AUGUST 28TH TO SAVE £100

Workshop B

Tumour Genomic Heterogeneity in ImmunotherapeuticsWorkshop Leaders: Michael G. Hanna, Jr. Founder &

Chairman Emeritus, Vaccinogen, Inc. 1.30pm - 5.30pm

Regist

ered

Attendees I

nclude:

Boehrin

ger Ingelheim

Imm

unicum

AB

Shio

nogi Ltd

Thera

vecty

s

CHAIR FOR 2015:Professor Farzin Farzaneh, Professor of MolecularMedicine, Kings College London

SPONSOR SPEAKER:Linda F. Powers, Chair and Chief Executive Officer,Northwest Biotherapeutics

FEATURED SPEAKERS INCLUDE: • Michael G. Hanna, Jr. Founder & Chairman Emeritus,

Vaccinogen, Inc. • Sebastian Kreiter, VP Immunotherapy, BioNTech RNA

Pharmaceuticals• Vaios Karanikas, Biomarker Experimental Medicine Leader,

Tumour Immunology, Roche Innovation Centre Zurich• Thomas Felzmann, CEO, Activartis Biotech GmbH • Peter L. Andersen, VP Vaccine R&D, Statens Serum Institut• Dr. Ravi Madan, National Cancer Institute• Felipe Bedoya, Director Product Development Laboratory,

University of Pennsylvania

Sponsor: Northwest Biotherapeutics

Register online at: www.cancervaccinesevent.com • Alternatively

Cancer Vaccines Day One | Wednesday 16th September 2015

8.30 Registration & Coffee

9.00 Chairman's Opening RemarksFarzin Farzaneh, Professor of Molecular Medicine, KingsCollege London

NEW FRONTIERS IN VACCINE DEVELOPMENT

OPENING ADDRESS:9.10 The Provocative Issue of Tumor Genetic Heterogeneity in

Immunotherapy•You cannot treat a Heterogeneous disease with a

Homogeneous treatment•Immunotherapy should be aimed at preventing recurrence

not treating established tumors•Immune longevity in Autologous Vaccine ImmunotherapyMichael G. Hanna, Jr. Founder & Chairman Emeritus,Vaccinogen, Inc.

9.50 Translational Biomarkers and Diagnostic Tools in Oncology•Analysis and interpretation to support key decisions during

the early clinical development •Enabling strategies and their implementation for early

preclinical/clinical studies •Validating the predictive utility of biomarker candidates Vaios Karanikas, Biomarker Experimental Medicine Leader,Tumour Immunology, Roche Innovation Centre Zurich

10.30 Morning Coffee

11.00 Establishing a fully-personalised cancer treatment•Phase I/II clinical trials •Augmenting T Cell response to •Vaccine and checkpoint blockade combinationsDr.Ravi Madan, National Cancer Institute

SUSTAINABLE CARE AND ANTI-TUMOUR RESPONSE

11.40 EFour into One does go: The use of integrated genomic,proteomic, immunological and bioinformatic platforms toidentify novel immunological biomarkers of disease andpredict outcomes of disease

•Tumour-mediated immunoregulation and immunologicalbarriers to successful therapeutic outcomes

•Immunomics: Integrating platforms for the discovery of newcancer biomarkers

•Case Study: Immunomics in prostate and breast cancerAlan Graham Pockley, Associate Director & Professor ofImmunobiology, Nottingham Trent University

12.20 Networking Lunch

1.30 DCVax®: Novel Personalized Immune Therapies for Solid Tumors•Ms. Powers will discuss NW Bio’s DCVax® platform

technology, a personalized, dendritic cell based activeimmunotherapy for solid tumors.

•Unlike conventional cancer drugs and other immunetherapies, which use one active agent to hit one target onthe cancer, DCVax mobilizes many active agents of theimmune system to hit many targets on the cancer.

Linda F. Powers, Chair and Chief Executive Officer, NorthwestBiotherapeutics

2.10 Combination therapies to advance immune-oncology vaccines and enhance patient outcomes •Multi-modal cancer immunotherapy

- combining vaccines & ICP inhibitors •Prognostic and Predictive Markers to Support

Identification of Effective Immunotherapy Combinations•Case studyThomas Felzmann, CEO, Activartis Biotech GmbH

2.50 Afternoon Tea

3.20 Understanding Tumor-Host Interactions•How to individualize cancer treatmentProfessor Dr. Dirk Jager, Director of Medical Oncology,National Center for Tumor Diseases, University Medical Center

4.00 Oncolytic virotherapy: Cancer immunotherapy as natureintended Hardev Pandha, Professor & Consultant Physician of MedicalOncology, Director, Surrey Cancer Research Institute,University of Surrey

4.40 PANEL DISCUSSION: Where is the future for Cancer Vaccines? •When should we use personalised and

non-personalised care? •How can we develop further understanding

in identifying novel pathways? •How accessible would fully - personalised treatments

become? •How will technology and data systems need to change

in order to allow personalised treatment to evolve? Panel leader: Farzin Farzenah, Professor of MolecularMedicine, Kings College LondonPanellists: Dr. Ravi Madan, National Cancer InstituteLinda F. Powers, Chair and Chief Executive Officer, NorthwestBiotherapeutics

5.20 Chairman's Closing Remarks and Close of Day One

5.30 Drinks reception - (5.30 - 7.00)Sponsored by Northwest Biotherapeutics

IndustryPerspective

Official media partners

SPONSORSHIP AND EXHIBITION OPPORTUNITIESSMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement yourcompany’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your clientbase within the context of an independent discussion specific to your industry. Should you wish to join the increasingnumber of companies benefiting from sponsoring our conferences please call: Alia Malick on+44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk

Northwest Bio is developing DCVax dendritic cell-based immunotherapeutic cancervaccines designed to treat a broad range of solid tumor cancers more effectively thancurrent treatments, and without the side effects of chemotherapy. The Company’s

lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients with newly diagnosed Glioblastomamultiforme (GBM), the most aggressive and lethal brain cancer. The Company’s second product, DCVax-Direct,is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers.

Sponsored by

Want to know how you can get involved? Interested in promoting your services to this market?

Contact Teri Arri, SMi Marketing on +44 (0) 207 827 6162, or email: tarri@smi-online.co.uk

fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711

Cancer VaccinesDay Two | Thursday 17th September 2015

8.30 Registration & Coffee

9.00 Chairman's Opening RemarksFarzin Farzaneh, Professor of Molecular Medicine, KingsCollege London

IMPROVEMENTS IN TARGETED RESPONSE

OPENING ADDRESS:9.10 Therapeutic Cancer Vaccines

•Tumour immunology and interactions between cancer andthe immune system

•Immune based sculpting of the tumour - selection of themost resistant cancer cells

•Cancer mediated immune suppression - inhibition ofsurveillance and stimulation of immune check points

•New therapeutic interventions: Active vaccinationstrategies, check point inhibition and targeted cytotolyticcells (CARs and TCR modified T cells)

Farzin Farzenah, Professor of Molecular Medicine, KingsCollege London

9.50 RNA - vaccinology: From ware-houses to activelypersonalized cancer vaccines •Simulating tumour-specific antigen recognition •Epitope Design Enables a Pipeline of Multi-Antigen DNA

Tumor Vaccines•Neo-antigen–specific CD4+ T cells recognize mutated

neo-antigensSebastian Kreiter, VP Immunotherapy, BioNTech RNAPharmaceuticals

10.30 Morning Coffee

11.00 Developments and clinical trials in allogeneic cell-basedvaccines•Deriving allogeneic dendritic cells for future scalability

and feasibility of cellular cancer vaccines•Practicalities of vaccine clinical trials •Cancer vaccine trial designs•Implementing targeting of known tumour antigensJohn Maudsley, CEO, Cancer Vaccines Ltd.

11.40 Case study: Dendritic cell vaccine development forcolorectal cancer.Eric Liere, CEO, DanDrit Biotech

12.20 Networking Lunch

1.30 Differentiation pathways of effector and memory CD8+ T cells•The protective role of memory CD8+ T cell subsets•Signaling pathways that regulate effector and memory

CD8+ T cell generation•Memory T cell subsets generated by vaccines and natural

infectionAymen Al-Shamkhani, Professor of Immunology, University ofSouthampton

2.10 Long-term maintenance of T cell memory by liposomes•Mode of action for cationic liposomes and the CAF

adjuvants•The role of central memory cells in the control of a chronic

infection - Experience from Tuberculosis•Data from clinical trialsPeter L. Andersen, VP Vaccine R&D, Statens Serum Institut

2.50 Round Table Discussion: Engineering materials to improve immune response •What are some of the biggest challenges that

limit immune response in DNA Vaccinations?•Development of combination treatments

- which ones are best?•Translating antigen expression - or lack of it

3.30 Peptides or DNA vaccines? Could Immunobody® be theanswer?•Long peptides vaccination require adjuvants but different

peptide work best with different adjuvant•DNA vaccine do not always generate high avidity T-cells•Could Immunobody® be the Universal antigen delivery

system? Stephanie McArdle, Senior Research Scientist, NottinghamTrent University

4.10 Gene Editing for Immunotherapy•Virus - vector to infiltrate the tumour •Discovery of Novel Targets for Genetic Engineering of

Tumor-Specific T Cells•Mutation-targeting RNA-based vaccinesFelipe Bedoya, Director Product Development Laboratory,University of Pennsylvania

4.50 Afternoon Tea

5.20 PANEL DISCUSSION: •Are we closer to achieving sustained

antitumor immune response?•Driving next generation tools in cancer

immunotherapy •What progresses in the Genome-wide mutation

identification initiatives have helped personalisedimmunology?

Panel leader: Farzin Farzenah, Professor of MolecularMedicine, Kings College LondonPanellists: Sebastian Kreiter, VP Immunotherapy, BioNTech RNAPharmaceuticalsPeter L. Andersen, VP Vaccine R&D, Statens Serum Institut

6.00 Chairman’s Closing Remarks and Close of Day Two

Supported by

Overview of workshop; Did you know that, in addition to being an intracellularmolecule, heat shock protein 70 (Hsp70) can be releasedfrom cancer cells, and that it is selectively expressed on theplasma membranes of wide range of tumour entities (~60 to80%)? Did you also know that chemo (radio) therapy canenhance the expression of this unique membrane form ofHsp70? This workshop will provide a comprehensive insightinto the approaches for tumour targeting and imaging thathave been developed using this platform, and thetheranostic potential of Hsp70 in oncology.

Key Benefits of Attending: This workshop is a unique opportunity to discuss thetherapeutic, targeting and imaging platforms that havebeen developed around this concept and how thetechnology might be able to enhance and improve currenttherapeutic approaches in a range of cancer settings. It willtherefore be of great interest and relevance to all thoseworking in pre-clinical and clinical diagnostic andtherapeutic translational oncology.

Programme

8.30 Registration and Coffee

9.00 Circulating Hsp70 as a biomarker of disease incancerDiscussion - A. Graham Pockley

9.30 Membrane Hsp70 expression in cancer and itstheranostic potentialDiscussion - Gabriele Multhoff

10.30 Coffee Break

11.00 Imaging and targeting of membrane Hsp70expressing tumours using a novel tumour-penetrating peptide (TPP) Discussion - Stefan Stangl

12.30 Conclusions & Close A. Graham Pockley & Gabriele Multhoff

About the workshop host: Graham Pockley is Professor of Immunobiology and theAssociate Director of the John van Geest Cancer ResearchCentre (JvGCRC) at Nottingham Trent University. He is alsothe CEO of multimmune GmbH, Munich. He has aninternational reputation in heat shock (stress) proteins andthe development and validation of new immunologicalassays and platforms in the fields of flow cytometry, immunemonitoring, and cell analysis.

About the organisation: The JvGCRC (www.ntu.ac.uk/vangeest)at Nottingham Trent University uses itsintegrated genomic, proteomic,immunological and bioinformatics

platforms to identify biomarkers of disease and diseaseprogression, predict therapeutic responses and the developdiagnostic and immunotherapeutic approaches.

Multimmune GmbH’s unique and proprietary technologyplatform is based on the discovery that a cell surface boundform of Hp70 is selectively expressed on many tumour typesby Gabriele Multhoff and Claus Botzler. multimmune isfocused on the development of innovative therapeuticapproaches for treatingcancers that express thiscell surface-expressedform of Hsp70.

HALF DAY PRE- CONFERENCE WORKSHOP ATuesday 15th September 2015

8.30am – 12.30pmMarriott Regents Park Hotel, London, UK

Stress is Good: Heat Shock Protein 70 asa Next-Generation Theranostic with

Broad Applicability in Oncology

Workshop Leaders:Alan Graham Pockley, 2Associate Director &Professor of Immunobiology, 2CEO, 3Founderand CEO 1Nottingham Trent University,2Multimmune GmbH, 3Chromocyte Ltd, UK

Prof. Gabriele Multhoff, 1University Professor in ExperimentelleRadioonkologie und Strahlenbiologie, and2Group Leader of Clinical Cooperation Groupin Tumor Biology, 1Technische UniversitätMünchen, 2Helmholz Zentrum München

Overview of workshop: Science highlighted cancer immunotherapy as the “2013Breakthrough of the Year”. More to the point, they stated"this year marks a turning point in cancer, as long-soughtefforts to unleash the immune system against tumors arepaying off - even if the future remains a question mark."Most of the celebration involves the compelling results oftargeted agents designed to reactivate the immunesystem by manipulating the PD-1/PD-L1 and CTLA-4pathways. Active specific immunotherapy (ASI) withcancer vaccines has the potential to be thattransformative technology by embracing the recentlydemonstrated genomic heterogeneity of tumor cellswhich represent the entire antigenic diversity of eachpatient’s primary tumor.

Key learning benefits from attending: • The impact in Antigen discovery for Cancer Vaccines • Patient population selection for treatment• In vivo and in vitro monitoring of the treatment and

clinical endpoints• Potential for development of epitope based vaccines

for treatment and prevention

Programme

1.30 Registration and Coffee

2.00 Antigen discovery for Cancer Vaccines

3.00 Afternoon Tea

3.30 Patient population selection for treatment

4.30 Potential for development of epitope basedvaccines for treatment and prevention

5.30 Close of workshop

About the workshop host:Dr. Michael G. Hanna, Jr. received his PhD in experimentalpathology and immunology from the University ofTennessee in 1964. He was on staff of the Oak RidgeNational Laboratory, biology division from 1964-75. Duringthis period he pioneered the early concepts of tumorimmunology. He also served as a consultant with NASA forthe lunar receiving laboratory during Apollo 11 and 12, forwhich his expertise in immunology was used in the testingof the lunar core powder for immunogenic or pathogenicmaterials. Dr. Hanna served during1975–83 as Director ofthe National Cancer Institute, Frederick Cancer ResearchCenter (MD, USA). In this position he created a center ofresearch excellence for the NCI and established theBiological Response Modifier Program which led in thedevelopment of resources for immunotherapy of cancer.

About the organisation: Vaccinogen, Inc. is a cancer vaccine company that isclinically testing its OncoVAX® treatment which isdesigned to prevent the recurrence of colon cancer andpotentially other solid tumors. It is a patented process thatcircumvents the extreme diversity of tumor cells byleveraging a patient’s own live tumor cells to launch abroad immune response against colon cancer. TheCompany believes that OncoVAX, at an optimum doseand regimen, is the first colon cancer vaccine todemonstrate effectiveness in both preventing cancerrecurrence after surgical resection of the primary tumorand addressing the diversity of cancer cells. OncoVAXhas completed five clinical studies, including a Phase IIItrial with the optimum dose and regimen. The Companyexpects to begin a pivotal Phase IIIb trial under an FDASpecial Protocol Assessment (SPA) classification in thesecond quarter of 2015. The Company’s shares trade onthe OTC.QB under the symbol “VGEN”. More informationis available at ww.vaccinogeninc.com 

HALF DAY PRE- CONFERENCE WORKSHOP BTuesday 15th September 2015

1.30pm – 5.30pmMarriott Regents Park Hotel, London, UK

Tumour Genomic Heterogeneityin Immunotherapies

Workshop Leader: Michael G. Hanna,Jr. Founder & Chairman Emeritus,Vaccinogen, Inc.

FAX your booking form to +44 (0) 870 9090 712PHONE on +44 (0) 870 9090 711

POST your booking form to: Events Team, SMi Group Ltd, 2nd FloorSouth, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK

CANCER VACCINES Conference: Wednesday 16th & Thursday 17th September 2015, Marriott Regents Park Hotel, London, UK

Workshops: Tuesday 15th September 2015, London, UK

4 WAYS TO REGISTERwww.cancervaccinesevent.com

If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk

Payment: If payment is not made at the time of booking, then an invoice will be issued and must bepaid immediately and prior to the start of the event. If payment has not been received then creditcard details will be requested and payment taken before entry to the event. Bookings within 7 daysof event require payment on booking. Access to the Document Portal will not be given until paymenthas been received.Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, anotherdelegate to take your place at any time prior to the start of the event. Two or more delegates maynot ‘share’ a place at an event. Please make separate bookings for each delegate.Cancellation: If you wish to cancel your attendance at an event and you are unable to send asubstitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providingthat cancellation is made in writing and received at least 28 days prior to the start of the event.Regretfully cancellation after this time cannot be accepted. We will however provide theconferences documentation via the Document Portal to any delegate who has paid but is unableto attend for any reason. Due to the interactive nature of the Briefings we are not normally able toprovide documentation in these circumstances. We cannot accept cancellations of orders placedfor Documentation or the Document Portal as these are reproduced specifically to order. If we haveto cancel the event for any reason, then we will make a full refund immediately, but disclaim anyfurther liability.Alterations: It may become necessary for us to make alterations to the content, speakers, timing,venue or date of the event compared to the advertised programme.Data Protection: The SMi Group gathers personal data in accordance with the UK Data ProtectionAct 1998 and we may use this to contact you by telephone, fax, post or email to tell you about otherproducts and services. Unless you tick here □ we may also share your data with third parties offeringcomplementary products or services. If you have any queries or want to update any of the data thatwe hold then please contact our Database Manager databasemanager@smi-online.co.uk or visitour website www.smi-online.co.uk/updates quoting the URN as detailed above your address on theattached letter.

Unique Reference Number

Our Reference LVP-150

Terms and Conditions of Booking

DELEGATE DETAILSPlease complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: Forename:

Surname:

Job Title:

Department/Division:

Company/Organisation:

Email:

Company VAT Number:

Address:

Town/City:

Post/Zip Code: Country:

Direct Tel: Direct Fax:

Mobile:

Switchboard:

Signature: Date:I agree to be bound by SMi's Terms and Conditions of Booking.

ACCOUNTS DEPT

Title: Forename:

Surname:

Email:

Address (if different from above):

Town/City:

Post/Zip Code: Country:

Direct Tel: Direct Fax:

VENUE Marriott Regents Park Hotel, 128 King Henry's Road, London, NW3 3ST

□ Please contact me to book my hotelAlternatively call us on +44 (0) 870 9090 711, email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712

□ Book by 29th May 2015 to receive £300 off the conference price□ Book by 30th June 2015 to receive £200 off the conference price□ Book by 28th August 2015 to receive £100 off the conference price

EARLY BIRDDISCOUNT

Payment must be made to SMi Group Ltd, and received before the event, by one ofthe following methods quoting reference P-150 and the delegate’s name. Bookingsmade within 7 days of the event require payment on booking, methods of paymentare below. Please indicate method of payment:

□ UK BACS Sort Code 300009, Account 00936418□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18□ Cheque We can only accept Sterling cheques drawn on a UK bank.□ Credit Card □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges.

Card No: □□□□ □□□□ □□□□ □□□□Valid From □□/□□ Expiry Date □□/□□CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card

Cardholder’s Name:

Signature: Date:I agree to be bound by SMi's Terms and Conditions of Booking.

Card Billing Address (If different from above):

DOCUMENTATIONI cannot attend but would like to purchase access to the following DocumentPortal/paper copy documentation Price Total□ Access to the conference documentation

on the Document Portal £499.00 + VAT £598.80□ The Conference Presentations – paper copy £499.00 - £499.00

(or only £300 if ordered with the Document Portal)

PAYMENT

VATVAT at 20% is charged on the attendance fees for all delegates. VAT is also charged onDocument portal and literature distribution for all UK customers and for those EU Customersnot supplying a registration number for their own country here.______________________________________________________________________________________________

CONFERENCE PRICESI would like to attend: (Please tick as appropriate) Fee Total□ Conference & 2 Workshops £2697.00 + VAT £3236.40□ Conference & 1 Workshop AM □ PM □ £2098.00 + VAT £2517.60□ Conference only £1499.00 + VAT £1798.80□ 1 Workshop only AM □ PM □ £599.00 + VAT £718.80□ 2 Workshops £1198.00 + VAT £1437.60

PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotional

literature to all conference attendees £999.00 + VAT £1198.80The conference fee includes refreshments, lunch, conference papers, and access to theDocument Portal. Presentations that are available for download will be subject todistribution rights by speakers. Please note that some presentations may not be availablefor download. Access information for the document portal will be sent to the e-mailaddress provided during registration. Details are sent within 24 hours post conference.